BioInvent

287 articles about BioInvent

• BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

  12/21/2020

  BioInvent International AB and Transgene announced they have received regulatory approval in Belgium for a clinical trial application for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001.

• Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

  12/21/2020

  Transgene and BioInvent International AB announced they have received regulatory approval in Belgium for a clinical trial application for a Phase 1/2a study of the novel oncolytic Vaccinia virus BT-001.

• Nomination Committee appointed for BioInvent International's Annual General Meeting 2021

  12/9/2020

  The members of the Nomination Committee for BioInvent International AB:s Annual General Meeting in 2021 have now been appointed.

• Record date for reverse share split in BioInvent International determined

  12/7/2020

  At the Extraordinary General Meeting of BioInvent International AB on 27 November 2020, a reverse share split was resolved upon, whereby twenty-five existing shares will be consolidated into one new share.

• Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020

  11/27/2020

  BioInvent International AB's Extraordinary General Meeting resolved to approve the Board of Directors' resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.

• BioInvent strengthens Investor Relations - Nov 27, 2020

  11/27/2020

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations.

• BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

  11/26/2020

  Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis.

• BioInvent presents new preclinical data on BI-1808, a first-in-class anti-TNFR2 antibody at the SITC 35th Anniversary Annual Meeting

  11/9/2020

  BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today   presents new data on BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) which is expected to enter Phase I

• BioInvent Interim Report January 1 - September 30, 2020

  10/29/2020

  The exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in China is an important validation of BioInvent's technology, expertise and business model.

• BioInvent Completes First Licensing Agreement in Greater China, Advised by MSQ Ventures

  10/28/2020

  M.S.Q. Ventures announced that its client, BioInvent International, AB, has successfully entered into a licensing agreement with CASI Pharmaceuticals, Inc. for the development and commercialization of BI-1206 in the Greater China region.

• Notice to Extraordinary General Meeting in BioInvent International AB

  10/27/2020

  As a part of the license agreement that BioInvent on this day has entered into with CASI Pharmaceuticals, Inc., as announced by way of separate press release, the Board of Directors has, subject to the approval by the general meeting, resolved to issue 29,395,311 new shares in the Company to CASI together with 14,697,655 new warrants.

• BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region

  10/27/2020

  CASI's pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid tumors

• CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial

  10/26/2020

  - BI-1808 is a novel mechanism of action antibody discovered through BioInvent's unique proprietary F.I.R.S.T™ technology platform - BI-1808 to be evaluated as monotherapy and in combination with anti-PD-1 antibody, Keytruda® - The first patients expected to be enrolled before year-end

• BioInvent receives €2 million milestone from Daiichi Sankyo

  10/22/2020

  BioInvent International AB announces that it will receive a €2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant directed antibody.

• BioInvent to present data on BI-1808, an anti-TNFR2 antibody, at the SITC 35th Anniversary Annual Meeting

  10/15/2020

  BioInvent International AB announce that they will be presenting a poster on BI-1808, an antibody to tumor necrosis factor receptor 2, at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.

• Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting

  10/15/2020

  Transgene, and BioInvent International AB announce that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.

• BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

  10/15/2020

  BioInvent International AB and Transgene announce that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.

• BioInvent Interim Report January 1 - June 30, 2020

  8/27/2020

  BioInvent is fully focused on moving our clinical projects forward. Our successful financing of SEK 625 million has strengthened our institutional investor base and is truly transformative for the company as it allows us to broaden and develop our exciting pipeline and creates a solid financial base going forward." Martin Welschof, CEO BioInvent.

• Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020

  8/21/2020

  BioInvent International AB will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m.

• BioInvent's BI-1206 could improve treatment in several cancers

  7/22/2020

  .Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July 21.